BRENNEN

Industries / Health / Pharmaceuticals

Preclinical testing

Testing a candidate in cells, tissues and animals to judge whether it is safe enough to try in people, and at what dose.

7

Milestones achieved, from 1959 to 2025.

1

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1959

    Replace, reduce, refine

    Russell and Burch, scholars of the Universities Federation for Animal Welfare (UFAW), published The Principles of Humane Experimental Technique. It set out the Three Rs: replacement, reduction and refinement of animal use. The UK's National Centre for the 3Rs says the principles are now embedded in national and international law on animal research.

    europepmc.orgnc3rs.org.uk

    Credit

    Russell and Burch, for UFAW

  2. 2006

    Six men in intensive care

    In March 2006 a first trial in people of TGN1412, an antibody meant to treat autoimmune diseases, put six men in intensive care at Northwick Park Hospital in London. Tests in monkeys had shown no such reaction, though monkeys carry an almost identical receptor for the antibody. A UK expert panel made 22 recommendations that December, including dosing volunteers one at a time, consulting outside experts on high-risk drugs and building a database of animal results.

    LessonPassing animal tests does not prove a first human dose is safe, above all for drugs that act on the immune system.

    nature.com

    Credit

    the UK expert scientific group that reviewed the trial

  3. 2010

    A lung on a chip

    D. Huh, D. E. Ingber and colleagues built a small device that copies the boundary between the air sacs and the blood vessels of the human lung. It stretched like a breathing lung, and that motion increased the toxic and inflammatory responses to silica nanoparticles. Devices of this kind are called organ-chips.

    europepmc.org

    Credit

    D. Huh, D. E. Ingber and colleagues

  4. 2012

    Few landmark results repeated

    Scientists at the biotech company Amgen tried to confirm 53 "landmark" preclinical cancer papers before building on them. The findings held up in 6 cases, or 11%. A Bayer team had reported the year before that about 25% of published preclinical studies could be validated.

    LessonA published result is not a validated drug target until someone repeats it.

    nature.com

    Credit

    C. G. Begley (Amgen) and L. M. Ellis

  5. 2022

    Animal-test wording dropped

    The FDA Modernization Act 2.0, passed in December 2022, replaced US legal wording that pointed drug makers to tests on animals with the broader term "nonclinical tests", and defined that term to include human-relevant methods such as cell-based and computer models.

    eara.eu

    Credit

    US Congress

  6. 2023

    530 drugs, one database

    M. Evangelisti and colleagues released a database of animal-study results for 530 approved drugs, taken from FDA pharmacology reviews, with effects in people taken from the drugs' labels. It links each observed or not-observed effect to its dose level, so animal and human findings can be compared.

    europepmc.org

    Credit

    M. Evangelisti and colleagues

  7. 2025

    FDA plans fewer animal tests

    On 10 April 2025 the FDA announced a plan to reduce, refine or replace animal testing for monoclonal antibodies (lab-made antibodies used as drugs) and other drugs. It named computer models, human cell lines, organoids and organ-chips, which it groups as new approach methodologies (NAMs), and said implementation would begin immediately. Its roadmap states that "no comprehensive database containing animal and human toxicity data currently exists".

    fda.govfda.gov

    Credit

    FDA

Watch for

  1. An organ-chip nears qualification

    Emulate submitted its full qualification package for its Human Liver-Chip to the FDA's ISTAND programme. Once the FDA qualifies a tool for a stated use, any company can use it with confidence that the FDA will accept the data. The stated use here is judging drug-induced liver injury. Emulate reports reproducible results across three laboratories and three donors of liver cells. An earlier study of 870 chips reported that they flagged 87% of the liver-toxic drugs and wrongly flagged none of the safe ones, in a blinded set of 27 drugs.

    Achieved whenthe FDA qualifies the chip for that use.

    pharmaceuticalonline.comeuropepmc.org

    Claimed by

    Emulate, September 2026

Open

  1. 01

    Beat the Liver-Chip on paper

    A computer model, trained only on public data, that sorts the same 27 benchmark drugs used in the Liver-Chip study into liver-toxic and safe, scored the same way the study scored the chip.

    The brief
    Credit · unclaimed
  2. 02

    Grow the toxicity database

    A pipeline that reads FDA pharmacology and toxicology reviews and drug labels, and fills the same fields as the 530-drug database: effect, species, dose level, severity and whether the effect went away. Use it to add the drugs approved since.

    The brief
    Credit · unclaimed

Open 01 · the brief

Beat the Liver-Chip on paper

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A computer model, trained only on public data, that sorts the same 27 benchmark drugs used in the Liver-Chip study into liver-toxic and safe, scored the same way the study scored the chip.

Why it is still open

The Liver-Chip's 87% sensitivity and 100% specificity on 27 blinded drugs is the result the FDA cites in its roadmap for cutting animal tests. I found no computer-only model scored on the same 27 drugs.

europepmc.orgfda.gov

Built with what exists

the FDA's DILIrank 2.0 dataset, which sorts 1,336 approved drugs into four classes of liver-injury concern; RDKit for chemical features; scikit-learn for the model; the list of 27 drugs from the Liver-Chip paper.

fda.gov

  1. First step

    Copy the 27 drugs and their labels from the Liver-Chip paper and remove them from a copy of DILIrank 2.0.

  2. Done looks like

    The model is frozen and published before it is scored, with the 27 drugs and their close chemical relatives removed from training. Its sensitivity and specificity on the 27 are reported beside the chip's, and an outside person reruns the code and gets the same numbers.

Open 02 · the brief

Grow the toxicity database

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A pipeline that reads FDA pharmacology and toxicology reviews and drug labels, and fills the same fields as the 530-drug database: effect, species, dose level, severity and whether the effect went away. Use it to add the drugs approved since.

Why it is still open

The FDA's April 2025 roadmap says no comprehensive database of animal and human toxicity data exists, and lists building an open one as a step it plans to take. The 2023 database stops at 530 drugs.

fda.goveuropepmc.org

Built with what exists

FDA review documents from Drugs@FDA; drug labels from DailyMed; a language model that reads scanned PDFs page by page and cites the page for each value, such as Claude or Gemini; the 530-drug database as the answer key. The note "Seven more flagged" covers a Claude-based reader of scanned drug-making records.

  1. First step

    Pick 10 drugs from the 530-drug set, run the pipeline on their FDA reviews and compare the results field by field.

  2. Done looks like

    On 50 drugs held back from the 530-drug set, at least 90% of extracted effect-and-dose entries match the curated values. Then 200 newer drugs are added, with a person checking 1 in 10 entries.